Kalyan Veerina, MD
Interventional Cardiology · Opelousas, LANPI 1619974557
Payments from drug & device makers
Across 935 payments — averaging $204.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vesper Medical$89K
- Inari Medical, Inc.$23K
- Imperative Care, Inc$17K
- Philips North America LLC$13K
- Penumbra, Inc.$11K
- Bard Peripheral Vascular, Inc.$9K
- plus $30K from 52 others
What the payments were for
- Consulting fees$9,97014%
- Speaking & faculty fees$7,20010%
- Travel & lodging$12,23417%
- Food & beverage$35,92350%
- Other$6,3809%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOOM 88-T LARGE DISTAL PLATFORM$8,550
- Indigo System$7,423
- VENOVO$6,447
- VenaCure 1470 Pro$6,380
- SYMPHONY CATHETER$2,843
- Penumbra Coil 400$2,742
- FLOWTRIEVER CATHETER, S$2,515
- Endurant$1,496
- Diamondback Peripheral$1,184
- PRODIGY CATHETER$1,061
- ENROUTE Transcarotid Neuroprotection System$1,057
- ENROUTE Transcarotid Stent System$1,057
- ENHANCE Transcarotid Peripheral Access Kit$1,057
- ENROUTE 0.014 Guidewire$1,057
- CT THROMBECTOMY SYSTEM KIT$1,035
- FlowTriever$928
- ClotTriever$928
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$754
- Abre$635
- Assure WCD$436
How this compares
$191,016 in reported general payments places this provider in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 456 | $342,194 |
| EliquisApixaban | 396 | $306,489 |
| EntrestoSacubitril/Valsartan | 155 | $139,100 |
| Repatha SureclickEvolocumab | 42 | $27,629 |
| Ranolazine ErRanolazine | 282 | $19,465 |
| FarxigaDapagliflozin Propanediol | 25 | $18,014 |
| MounjaroTirzepatide | 17 | $17,060 |
| ClopidogrelClopidogrel Bisulfate | 1,506 | $10,716 |
| Nebivolol Hcl | 173 | $7,769 |
| Praluent PenAlirocumab | 15 | $7,725 |
| VascepaIcosapent Ethyl | 20 | $7,622 |
| Metoprolol Succinate | 690 | $6,174 |
| Atorvastatin Calcium | 789 | $5,330 |
| Amlodipine Besylate | 810 | $4,588 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 17 | $3,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $522 | $342,194456 claims |
| PfizerEliquis | $665 | $306,489396 claims |
| NovartisEntresto | $1,953 | $139,100155 claims |
| AstraZenecaFarxiga | $91 | $18,01425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Opelousas
- David HomanOpelousas$90K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
- Stephen RameeNew Orleans$1.5M
- Denzil MoraesBaton Rouge$1.4M
- James JenkinsNew Orleans$1.2M
- Ankur LodhaLafayette$945K
- Rajan PatelNew Orleans$633K
- Bruce EnnisMandeville$562K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.